On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS JB Banks on Sustained Aid to Double Plasma Processing Capacity
October 27, 2026
-
BUSINESS Japan Pharma Earnings Season Opens as Drug Price Cuts, Patent Cliffs Test Growth
October 27, 2026
-
BUSINESS Wholesalers See NHI-Market Price Gap Falling Below 4.8% to New Record Low
October 26, 2026
-
BUSINESS Japan’s 1st Xolair Biosimilar Finally Set for December Launch after Delays
October 23, 2026
-
REGULATORY Japan Weighs Possible Approval Revocation for Tavneos, Action Against Kissei
October 22, 2026
-
BUSINESS Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
-
BUSINESS Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
-
REGULATORY LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
-
COMMENTARY Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026
-
REGULATORY CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
-
REGULATORY Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
-
ORGANIZATION Japan Falling Behind US, China in Pharma Innovation, EFPIA Chief Urges Action
October 15, 2026
-
BUSINESS Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
-
ORGANIZATION US VC Coalition Urges Japan to Rethink Drug Pricing, Labor Rules
October 13, 2026
-
REGULATORY Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
-
BUSINESS TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
-
REGULATORY Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
-
ACADEMIA HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
-
ORGANIZATION PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
-
BUSINESS LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…